Every material Form 8-K FibroBiologics, Inc. has filed with the SEC since September 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
FibroBiologics sold Peak One Opportunity Fund a $1.2 million convertible debenture for $1,020,000, a 15% original issue discount, and issued 125,000 restricted commitment shares. The debenture matures October 8, 2027, and is convertible only after an Event of Default, at a fixed $0.78 per share. Shareholders face possible dilution and near-term repayment obligations, with the company's interim payments of $1,080,000 due in April 2027.
Debenture principal of $1,200,000 sold for $1,020,000, with 0% interest and a maturity date of October 8, 2027
Interim payments of $1,080,000 due April 8, 2027, and $60,000 due July 8, 2027, with the balance at maturity
Conversion only after an Event of Default, at $0.78 per share; issuance capped at 1,671,094 shares absent stockholder approval
Company issued 125,000 commitment shares and paid a $20,000 non-accountable fee to Peak One
At a September 17, 2026 special meeting, FibroBiologics stockholders approved the issuance of up to 8,163,266 shares under warrants tied to a June 25, 2026 Securities Purchase Agreement and up to 285,714 shares under warrants tied to an H.C. Wainwright engagement letter, for purposes of Nasdaq Listing Rule 5635(d). Separately, Chief Scientific Officer Hamid Khoja closed a private placement on September 15, 2026 for 298,508 shares and accompanying warrants, with gross proceeds of about $0.5 million.
Special meeting held September 17, 2026; 3,431,761 of 8,283,193 votes entitled to be cast (record date July 20, 2026) were represented.
Approval covers up to 8,163,266 shares under the June 25, 2026 SPA warrants and up to 285,714 shares under H.C. Wainwright warrants.
Khoja private placement closed September 15, 2026 at $1.675 per share-and-warrant unit, priced at-the-market; warrants exercisable at $1.55 for five years.
FibroBiologics agreed on September 15, 2026 to sell 298,508 shares of common stock and accompanying warrants to Chief Scientific Officer Hamid Khoja, Ph.D., in a private placement. Gross proceeds are expected to be about $0.5 million, which the company plans to use for general corporate purposes and working capital, so the sale adds a small number of shares and potential future shares for existing holders.
Shares offered at $1.675 each, equal to the September 14, 2026 Nasdaq closing bid of $1.55 plus $0.125 per warrant
Warrants are exercisable at $1.55 per share, expire five years after issuance, and allow cashless exercise
Maximum of 298,508 shares could be issued on warrant exercise, subject to anti-dilution adjustments
The offering is expected to close on September 15, 2026, subject to customary closing conditions
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every FibroBiologics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →